Nearly $800,000 in U.S. health funds flowed to a project tied to a Russian institute with plague roots, and the paper trail raises hard questions about judgment and risk management at the very top of health policy.
Story Snapshot
- Federal records show two National Institutes of Health payments in 2025 and 2026 totaling about $779,689 for a U.S.-Russia research tie-up.
- The U.S. partner was the University of Illinois Urbana-Champaign; the foreign partner was Russia’s state-run Institute of Cytology and Genetics, linked in reporting to a Siberian anti-plague network.
- The funding arrived as global attention focused on a death of a lab worker tied to Russia’s plague research system, spotlighting biosafety and transparency concerns.
- Critics say the decision reflects poor judgment and lax guardrails over risky collaborations during tense U.S.-Russia relations.
What The Money Was, Who Got It, And When
Federal grant records cited by Mediaite show the National Institutes of Health awarded $779,689 to the University of Illinois Urbana-Champaign across two disbursements: $389,943 in July 2025 and $389,746 in September 2026. The project included a collaboration with Russia’s state-run Institute of Cytology and Genetics. That institute has been described in reporting as connected to the country’s anti-plague research system, which has roots in Soviet-era disease control and biodefense work. The payments were made under Health and Human Services leadership that included Robert F. Kennedy Jr..
The grant’s purpose has not been detailed in full in the public reporting, but the controversy does not hinge on a secret. The core facts are straightforward: U.S. taxpayer funds supported research involving a Russian government institute that sits in the historical shadow of plague research. That creates three policy questions at once: grant propriety, biosafety posture, and the wisdom of partnering with a state actor at odds with U.S. interests. Those questions are fair, and they demand clear, documented answers from health leadership.
Why Russia’s Plague Infrastructure Raises The Stakes
Modern Russia maintains a network of anti-plague institutions that date back to the 1930s, focused on plague and other high-consequence pathogens. The recent death of a 28-year-old lab worker tied to that ecosystem put a bright light on safety, reporting, and international obligations. The Washington Post described the Irkutsk Anti-Plague Institute’s origins and its expansion to other dangerous diseases, underscoring why any tie to this system gets extra scrutiny from the public and from global health watchers. That context makes any U.S.-linked funding look larger than a line item.
The public also sees the pattern. When studies touch dangerous agents, cross borders, or involve opaque institutions, suspicion spikes before the paperwork even posts. That is not paranoia; it is a rational reaction to high stakes. Governments should respect that instinct with more sunlight, not less. They should publish the aims, define the biosafety rules, and show the stop-switches. If the science is sound and the guardrails are tight, prove it on paper and in practice.
What Critics Are Saying, And The Leadership Test It Sets
Commentators have framed this as a leadership failure and a preventable risk. Television host Ana Navarro blasted the decision as proof of poor qualifications and poor Senate judgment in confirming the health chief, reflecting a wider worry about competence in high-hazard domains. That critique lands with force for readers who value common sense guardrails: know your partners, know your risks, and do not subsidize gray-zone research with geopolitical rivals. A tough question follows: who signed off, and why was this the best option available?
🚨BREAKING: RFK is funding an NIH grant with a Siberian plague lab collaborator.
– A new White Coat Waste (WCW) investigation exposes $779,689 in new NIH funding under Secretary Robert F. Kennedy Jr. for an animal experimentation collaboration with a Russian lab that has…
— White Coat Waste (@WhiteCoatWaste) October 8, 2026
Supporters of international health work often argue that engagement can raise safety standards and promote transparency. That can be true when the partner shares data and honors obligations. But recent events in Russia have driven calls for outside clarity. The World Health Organization and major outlets pressed Moscow to provide more details about the lab worker’s death and any pathogen risk, a reminder that trust must be earned with verifiable information. Funding decisions should reflect that reality on the front end.
The Policy Fix: Build Bright Lines And Publish Them
Congress and the executive branch should set bright, public lines for high-risk foreign collaborations. First, name prohibited partners and high-risk categories by statute, not by memo. Second, require a transparent, pre-award biosafety and foreign influence review for any project with high-consequence pathogens. Third, publish non-sensitive grant rationales so taxpayers can see the why, not only the what. These steps match conservative values: accountability, prudent stewardship, and a bias for domestic capability over risky outsourcing.
Health leaders should also report to relevant committees with a simple checklist: pathogen risk level, partner track record, data-sharing terms, on-site inspection rights, and rapid-termination triggers. If a project cannot pass that test in daylight, it should not pass at all. The lesson from this episode is not to halt science. It is to harden the rules, pick partners who meet them, and keep the American public fully informed before money moves, not after.
Sources:
mediaite.com, apnews.com, whitecoatwaste.org
